GlassScriptPhysician profile
James L Bridgeman
NPI 1700811593
$13,375.47
in general payments reported to CMS, 2019-2025
59 companies · $2,442 in 2025
The $2,442 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,566 · 2020: $902 · 2021: $1,555 · 2022: $1,914 · 2023: $2,576 · 2024: $2,421 · 2025: $2,442.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,264 · Consulting Fee: $175.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,264.37 |
| Consulting Fee | $175.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,725.02 | 2019-2025 | Vraylar, Qulipta, Ubrelvy |
| Novo Nordisk INC | $1,661.03 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $1,003.34 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $842.70 | 2020-2025 | |
| Astrazeneca Pharmaceuticals LP | $823.69 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $619.22 | 2019-2025 | Prolia, Otezla, Repatha |
| Bayer Healthcare Pharmaceuticals INC. | $489.34 | 2021-2025 | |
| Abbott Laboratories | $438.69 | 2019-2025 | Freestyle Libre 3, Freestyle Libre 2, Proclaim |
| Lundbeck LLC | $402.62 | 2022-2025 | Vyepti, Rexulti |
| Glaxosmithkline, LLC. | $396.85 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astellas Pharma US INC | $367.26 | 2019-2025 | Veozah, Myrbetriq |
| Exact Sciences Corporation | $347.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $295.76 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $291.84 | 2021-2025 | Spravato |
| Allergan, INC. | $284.47 | 2019-2020 |
Show all 59 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Bridgeman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.